SEC Imposes $35M Fine On Wells Fargo For Overcharging Advisory Fees

Wells Fargo & Company (NYSE: WFC) has been charged a $35 million civil penalty by the Securities and Exchange Commission for overcharging more than 10,900 investment advisory accounts over $26.8 million in advisory fees. 

Wells Fargo & Company (NYSE:WFC) has been charged a $35 million civil penalty by the Securities and Exchange Commission for overcharging more than 10,900 investment advisory accounts over $26.8 million in advisory fees. 

The regulatory watchdog claimed that Wells Fargo and its predecessor firms overcharged certain clients who opened accounts before 2014 for advisory fees through the end of December 2022.

“For years, Wells Fargo and its predecessor firms negotiated reduced advisory fees with thousands of clients, but failed to honor them, overcharging those clients millions of dollars as a result,” said Gurbir S. Grewal, Director of the SEC’s Enforcement Division. 

Also Read: Wells Fargo Faces Potential NLRB Action Over Labor Law Violations at Oregon Call Center

Wells Fargo paid affected accountholders approximately $40 million, including interest, to reimburse them for the overcharging. 

“Today’s enforcement action underscores the need for firms growing their businesses through acquisition to ensure that their growth does not come at the expense of client protection,” Grewal added.

Last year, the Consumer Financial Protection Bureau accused Wells Fargo of widespread mismanagement of auto loans, mortgages, and deposit accounts. 

The bank was asked to pay more than $2 billion in redress to consumers and a $1.7 billion civil penalty for legal violations across several of its largest product lines.

Photo Via Company

Total
0
Shares
Related Posts
Read More

Immutep Announced New Patent Granteds in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10- 2441425) entitled "Combined Preparations for the Treatment of Cancer" by the Japanese Patent Office and South Korean Patent Office, respectively

IMMP